The Cooper Companies, Inc.
- Open
- 70.61
- Day high
- 71.53
- Day low
- 70.20
- Prev close
- 71.59
- Volume
- 125K
- Mkt cap
- $14.0B
- P/E (TTM)
- 60.6
- EPS (TTM)
- $1.18
- P/B
- 1.7
- P/S
- 3.3
- Yield
- —
- Per share
- —
The Cooper Companies, Inc. (COO) is a Healthcare company listed on NASDAQ. The stock is up 1% over the past year.
The Cooper Companies, Inc. (COO) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 9 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
COO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jun 4, 2026 | $1.10 | $1.21 | +10.0% | $1.1B | +2.6% |
| Mar 5, 2026 | $1.03 | $1.10 | +6.8% | $1.0B | -2.8% |
| Dec 4, 2025 | $1.11 | $1.15 | +3.6% | $1.1B | +0.4% |
| Aug 27, 2025 | $1.07 | $1.10 | +2.8% | $1.1B | -0.3% |
| May 29, 2025 | $0.93 | $0.96 | +3.4% | $1.0B | +0.7% |
| Mar 6, 2025 | $0.91 | $0.92 | +0.7% | $965M | -1.4% |
| Dec 5, 2024 | $1.00 | $1.04 | +4.0% | $1.0B | -0.8% |
| Aug 28, 2024 | $0.91 | $0.96 | +5.4% | $1.0B | +0.6% |
| May 30, 2024 | $0.83 | $0.85 | +2.5% | $943M | -0.6% |
| Feb 29, 2024 | $0.78 | $0.85 | +8.6% | $932M | +1.7% |
| Dec 7, 2023 | $0.87 | $0.87 | +0.0% | $927M | +0.2% |
| Aug 30, 2023 | $0.84 | $0.84 | +0.0% | $930M | +0.8% |
COO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 6, 2026 | Keel Paul Adirector | Grant | 2,814 | — |
| Apr 21, 2026 | Rosebrough Walter M Jrdirector | Option | 832 | — |
| Apr 21, 2026 | Rosebrough Walter M Jrdirector | Grant | 832 | — |
| Apr 6, 2026 | WEISS ROBERT Sdirector | Grant | 3,779 | — |
| Apr 6, 2026 | Jay Colleendirector | Option | 3,322 | — |
| Apr 6, 2026 | MADDEN TERESA Sdirector | Grant | 3,779 | — |
| Apr 6, 2026 | Kurzius Lawrence Erikdirector | Option | 3,322 | — |
| Apr 6, 2026 | Kurzius Lawrence Erikdirector | Grant | 3,779 | — |
| Apr 6, 2026 | Carbone Barbaradirector | Option | 3,050 | — |
| Apr 6, 2026 | Jay Colleendirector | Grant | 4,157 | — |
| Apr 6, 2026 | Carbone Barbaradirector | Grant | 3,779 | — |
| Apr 6, 2026 | Rivas Mariadirector | Option | 3,322 | — |
| Apr 6, 2026 | Lucchese Cynthia Ldirector | Option | 3,322 | — |
| Apr 6, 2026 | Rivas Mariadirector | Grant | 3,779 | — |
| Apr 6, 2026 | WEISS ROBERT Sdirector | Option | 3,654 | — |
Source: COO SEC Form 4 filings, latest Jul 6, 2026. For informational purposes only — not investment advice.
See the full COO insider & 13F page →The Cooper Companies, Inc. company profile
Overview
The Cooper Companies, Inc. (NYSE:COO) is a global medical device company founded in 1958 and headquartered in San Ramon, California. The company has evolved from its origins into a leading manufacturer of contact lenses and women's healthcare products. Cooper Companies went public in 1983 and has grown through strategic acquisitions and organic expansion to become a significant player in the medical devices industry, operating in over 100 countries worldwide with annual revenues approaching $4 billion.
Business
The Cooper Companies operates in the medical devices sector through two primary business segments that serve distinct healthcare markets. CooperVision represents the company's contact lens division and generates approximately 65-70% of total revenues. This segment develops, manufactures, and markets a comprehensive portfolio of contact lenses designed to correct various vision problems. The product lineup includes spherical lenses for basic nearsightedness and farsightedness correction, toric lenses for astigmatism, and multifocal lenses for presbyopia (age-related reading difficulties). A key growth area is daily silicone hydrogel lenses, particularly the MyDay and Clarity product lines, which offer superior comfort and eye health benefits compared to traditional hydrogel materials. The division also focuses heavily on myopia management, offering specialized lenses like MiSight that are designed to slow the progression of nearsightedness in children - a growing global health concern as myopia rates increase due to increased screen time and lifestyle changes. CooperSurgical comprises the women's healthcare and fertility business, accounting for approximately 30-35% of total revenues. This segment provides medical devices, fertility treatments, genomic testing, and contraceptive products to healthcare professionals worldwide. The fertility business offers consumables and equipment for assisted reproductive technology procedures, embryo testing services, and preimplantation genetic testing. The office and surgical products division manufactures instruments for gynecological procedures, including the PARAGARD copper intrauterine device (IUD) - the only hormone-free IUD available in the United States. Other products include surgical instruments, diagnostic equipment, and various medical devices used in women's healthcare procedures.
Revenue model
Cooper Companies generates revenue primarily through product sales to healthcare professionals, distributors, and retail chains across global markets. The business model varies slightly between segments but centers on manufacturing and selling medical devices with recurring usage patterns. CooperVision operates on a consumable product model where contact lenses require regular replacement - daily lenses provide the most frequent repurchase cycle, followed by weekly and monthly replacement schedules. The company sells through eye care professionals, optical chains, and online retailers, with pricing varying by product sophistication. Higher-margin specialty lenses like torics, multifocals, and myopia management products command premium pricing due to their advanced technology and smaller addressable markets. Geographic expansion, particularly in developing markets with growing middle-class populations, drives volume growth. CooperSurgical generates revenue through both consumable products used in medical procedures and durable medical equipment sales. The fertility business benefits from recurring demand as patients often require multiple treatment cycles, while the contraceptive and surgical instrument businesses depend on procedure volumes and device replacement cycles. PARAGARD provides a particularly attractive revenue stream due to its 10-year lifespan and premium positioning as the only non-hormonal IUD option. Margin expansion opportunities include shifting product mix toward higher-value specialty lenses, expanding manufacturing efficiency, and leveraging economies of scale in R&D investments. Margin pressures can arise from raw material cost inflation, competitive pricing dynamics, regulatory compliance costs, and the need for continuous innovation investments. Currency fluctuations significantly impact margins given the company's global manufacturing footprint and sales exposure. Healthcare reimbursement changes, particularly in fertility treatments, can also influence demand patterns and pricing power.
Competitive moat
Cooper Companies possesses a moderate competitive moat built primarily on technological expertise, regulatory barriers, and market positioning advantages, though the strength varies significantly between business segments. In contact lenses, the company benefits from substantial R&D investments and manufacturing expertise required to produce advanced silicone hydrogel materials and specialty lens designs. The regulatory approval process creates barriers to entry, particularly for innovative products like myopia management lenses where Cooper holds key patents and clinical data. However, the contact lens market faces intense competition from large players like Johnson & Johnson and Alcon, limiting pricing power. The shift toward daily lenses favors companies with efficient manufacturing capabilities, where Cooper has invested heavily. CooperSurgical's moat is stronger in specific niches, particularly with PARAGARD as the sole hormone-free IUD in the U.S. market, providing significant competitive protection until potential new entrants receive regulatory approval. The fertility business benefits from relationships with specialized clinics and the technical expertise required for assisted reproductive technology, though this market remains fragmented with multiple competitors. The primary competitive threats include larger medical device companies with greater R&D resources, potential technological disruptions in vision correction (such as advanced surgical procedures or pharmaceutical alternatives), and new entrants in the fertility market. Generic competition poses ongoing risks, particularly as patents expire on key products. The company's global manufacturing footprint provides some protection through cost advantages and supply chain resilience, but technological innovation remains the primary differentiator in maintaining market position.
Risks & safety
Cooper Companies demonstrates a solid financial position with moderate margin of safety characteristics: • Liquidity and Solvency: Current ratio of 2.1x indicates strong short-term liquidity. Debt-to-equity ratio of 0.31x represents conservative leverage levels. Free cash flow of approximately $300-400 million annually provides adequate cash generation for operations and investments. • Valuation Metrics: Trading at P/E ratio of 46-53x based on recent earnings, indicating premium valuation. EV/EBITDA of 17-21x suggests the stock is priced for continued growth execution. Price-to-book ratio of 2.0-2.6x reflects asset-light business model with significant intangible value. • Other Considerations: Strong EBITDA margins around 27-28% demonstrate operational efficiency. Return on equity of 4-5% appears modest but reflects heavy reinvestment in growth initiatives. The company maintains investment-grade credit characteristics with consistent cash flow generation, though growth investments limit current profitability metrics.
Recent development
Over the past few years, Cooper Companies has executed several strategic initiatives focused on expanding market leadership and driving innovation across both business segments. The company has significantly increased manufacturing capacity for its MyDay contact lens product line to meet growing demand, particularly in international markets where the product continues to gain market share. A major strategic pivot involves the aggressive expansion of the myopia management business, with MiSight lenses showing 35-50% growth rates as the company implements free trial programs to reduce adoption barriers for parents and children. In the fertility business, Cooper has made substantial investments following the acquisition of Generate Life Sciences, positioning the company as a comprehensive fertility solutions provider. The company has worked through operational challenges, including a culture media recall that temporarily impacted the fertility segment, while continuing to invest in product innovation and expanding service offerings. Recent launches include expanding the MyDay product portfolio internationally and preparing for the launch of MyDay MySite, specifically designed for myopia management applications. The company has also focused on operational efficiency improvements, implementing IT system upgrades, enhancing employee training programs, and optimizing manufacturing processes to improve margins. Strategic pricing initiatives across both segments help offset inflationary pressures while the company evaluates supply chain adjustments in response to potential trade policy changes. These developments reflect Cooper's commitment to maintaining technological leadership while expanding global market presence in attractive, growing healthcare segments.
COO company profile · for informational purposes only — not investment advice.
Track COO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free